Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) Director Mace Rothenberg bought 10,000 shares of the stock in a transaction dated Thursday, November 14th. The stock was bought at an average price of $3.62 per share, with a total value of $36,200.00. Following the acquisition, the director now owns 21,250 shares in the company, valued at approximately $76,925. This represents a 88.89 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Mace Rothenberg also recently made the following trade(s):
- On Monday, November 18th, Mace Rothenberg purchased 10,000 shares of Tango Therapeutics stock. The shares were bought at an average price of $3.78 per share, for a total transaction of $37,800.00.
Tango Therapeutics Stock Performance
TNGX stock opened at $3.60 on Tuesday. The stock's 50 day moving average price is $6.65 and its 200 day moving average price is $8.15. The firm has a market cap of $386.71 million, a P/E ratio of -3.05 and a beta of 0.88. Tango Therapeutics, Inc. has a 1 year low of $2.70 and a 1 year high of $13.01.
Institutional Trading of Tango Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in TNGX. Point72 DIFC Ltd purchased a new stake in Tango Therapeutics during the 2nd quarter worth about $54,000. Paloma Partners Management Co purchased a new position in shares of Tango Therapeutics during the first quarter valued at approximately $80,000. Principal Financial Group Inc. acquired a new stake in Tango Therapeutics during the second quarter worth approximately $90,000. Quest Partners LLC boosted its position in Tango Therapeutics by 1,448.4% during the third quarter. Quest Partners LLC now owns 10,885 shares of the company's stock worth $84,000 after acquiring an additional 10,182 shares during the last quarter. Finally, Quarry LP purchased a new stake in Tango Therapeutics in the 2nd quarter worth approximately $99,000. 78.99% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Trump won. Buy this coin now.
From Weiss Ratings | Ad
Juan Villaverde called the top and bottom of every crypto bull market since 2012.
He believes Bitcoin will go to $150,000 — or more.
But there’s one coin he thinks could go even higher.
This could be his favorite coin.
Several brokerages have issued reports on TNGX. Guggenheim dropped their price objective on Tango Therapeutics from $18.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. HC Wainwright reiterated a "buy" rating and set a $13.00 target price on shares of Tango Therapeutics in a research note on Friday, November 8th. B. Riley lowered their price objective on shares of Tango Therapeutics from $16.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, November 11th. Finally, Wedbush increased their target price on Tango Therapeutics from $11.00 to $13.00 and gave the stock an "outperform" rating in a research note on Thursday, August 8th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Tango Therapeutics has a consensus rating of "Buy" and an average target price of $13.14.
View Our Latest Report on Tango Therapeutics
Tango Therapeutics Company Profile
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
